Good times for nanotechnology companies. The Berlin-based Capsulution Nanoscience AG fulfilled its turnover expectations in 2006 with more than 1.3 million euro. In comparison to the year before, the developer of nanotechnological “active component packages” managed with this an increase of about 50 %. The personnel figures rose to a final 20 members of staff, more than half of which are highly-qualified scientists and laboratory staff in the field of research and development.
As well as carrying out numerous customer projects, Capsulution has undertaken vital steps to test its own technology in preclinical studies and adapt to the requirements of industrial customers, evident in its collaboration with the Charité, started at the end of 2006. Due to such preliminary developments, the EBIT margin with about TEUR -150 still turned out negatively. “With this operational result, our company is clearly faring better than many other start-up technology companies in the same field”, states Alexander Herrmann, CFO.
Herrmann is optimistic about the year to come: “Our aim is not only to increase the turnover to double figures but also to break even.” These high expectations are based not in the least on the positive developments of the past months. Since November, Capsulution has, with the additional granting of its basis patent for its LBL Technology yet another competitive edge on
Speaking for the good growth prognoses are further well-known partner and customer acquisitions with commissioned developments in innovative nanoproducts forged in the last year, such as the published developments with the Schering AG (today Bayer Schering Pharma AG) or the Eyesense AG.